| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAPD5 |
| Uniprot No | Q8NDF8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-572 aa |
| 活性数据 | MYRSGERLLGSHALPAEQRDFLPLETTNNNNNHHQPGAWARRAGSSASSPPSASSSPHPSAAVPAADPADSASGSSNKRKRDNKASGGRAAGGGRADGGGVVYSGTPWKRRNYNQGVVGLHEEISDFYEYMSPRPEEEKMRMEVVNRIESVIKELWPSADVQIFGSFKTGLYLPTSDIDLVVFGKWENLPLWTLEEALRKHKVADEDSVKVLDKATVPIIKLTDSFTEVKVDISFNVQNGVRAADLIKDFTKKYPVLPYLVLVLKQFLLQRDLNEVFTGGIGSYSLFLMAVSFLQLHPREDACIPNTNYGVLLIEFFELYGRHFNYLKTGIRIKDGGSYVAKDEVQKNMLDGYRPSMLYIEDPLQPGNDVGRSSYGAMQVKQAFDYAYVVLSHAVSPIAKYYPNNETESILGRIIRVTDEVATYRDWISKQWGLKNRPEPSCNGPVSSSSATQSSSSDVDSDATPCKTPKQLLCRPSTGNRVGSQDVSLESSQAVGKMQSTQTTNTSNSTNKSQHGSARLFRSSSKGFQGTTQTSHGSLMTNKQHQGKSNNQYYHGKKRKHKRDAPLSDLCR |
| 分子量 | 79.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PAPD5蛋白的3篇文献参考示例：
1. **文献名称**：*PAPD5-mediated 3' adenylation of mammalian RNase H1 regulates RNA-DNA hybrid resolution*
**作者**：Jones, M. et al.
**摘要**：该研究解析了重组人PAPD5蛋白的酶活机制，证实其通过腺苷酸化修饰调控RNase H1的3'端结构，影响RNA-DNA杂交体的代谢，揭示其在维持基因组稳定性中的作用。
2. **文献名称**：*Structural and functional characterization of PAPD5 in telomerase RNA component maturation*
**作者**：Li, X. et al.
**摘要**：通过体外重组表达PAPD5蛋白，结合冷冻电镜技术揭示了其与端粒酶RNA组分(TERC)的相互作用，证明PAPD5对TERC的3'端修饰至关重要，为端粒酶功能异常相关疾病的治疗提供新靶点。
3. **文献名称**：*PAPD5 inhibition as a therapeutic strategy for dyskeratosis congenita-associated ribosomopathies*
**作者**：Garcia, J. et al.
**摘要**：研究报道了重组PAPD5蛋白在先天性角化不良症中的作用，发现抑制PAPD5可减少异常核糖体RNA的腺苷酸化，改善细胞翻译功能，提示靶向PAPD5是治疗该疾病的潜在策略。
(注：以上文献为模拟参考，实际文献需通过PubMed/Google Scholar检索确认。)
Recombinant human PAPD5 (Poly(A) polymerase-associated domain-containing protein 5), also known as TRF4-1. is a non-canonical poly(A) polymerase belonging to the TRAMP (TRF4/5-Air1/2-Mtr4 polyadenylation) complex. It plays a regulatory role in RNA quality control and degradation by adding oligo(A) tails to aberrant or misfolded RNAs, marking them for exosome-mediated degradation. Structurally, PAPD5 contains a conserved N-terminal catalytic domain with poly(A) polymerase activity and a C-terminal domain involved in protein interactions.
This protein is critical in maintaining RNA homeostasis, particularly in processes like rRNA processing, telomerase RNA (TERC) stability, and microRNA maturation. Dysregulation of PAPD5 has been linked to diseases such as dyskeratosis congenita (a telomere disorder) and certain cancers, where its aberrant activity can impair telomere maintenance or promote oncogenic RNA stabilization. Recent studies highlight its potential as a therapeutic target; inhibiting PAPD5 may rescue TERC deficits in genetic disorders, while modulating its activity could influence cancer cell proliferation.
Recombinant PAPD5 is typically produced in *E. coli* or mammalian expression systems for functional studies. Its biochemical characterization, including RNA-binding assays and polyadenylation activity tests, has advanced understanding of post-transcriptional RNA regulation, offering insights into both fundamental biology and clinical applications.
×
